Recruiting nowPhase 2
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Updated 2026-05-26 · NCT07221214See eligibility →
Treatment
Semaglutide (Rybelsus®) clinical trials
Active studies that list Semaglutide (Rybelsus®) as an intervention or treatment.
10active studies
5recruiting now
3countries represented
1largest site network
Current studies
Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.
Recruiting nowPhase 4
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
Updated 2026-02-11 · NCT07401992See eligibility →
Updated 2026-01-05 · NCT07295223See eligibility →
Recruiting nowPhase 3
Epicardial Cardiac Fat-CT (EPIC-CT)
Updated 2026-01-02 · NCT07297589See eligibility →
Recruiting nowEarly Phase 1
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Updated 2025-12-18 · NCT06338553See eligibility →
Updated 2026-06-11 · NCT07642635See eligibility →
Opening soonPhase 2
Oral Semaglutide in Patients With Alzheimer's Disease
Updated 2025-10-01 · NCT07200622See eligibility →
Updated 2025-09-17 · NCT07179120See eligibility →
Opening soonPhase 2
Improved Treatment and Monitoring of Alzheimer's Disease
Updated 2025-08-22 · NCT07135245See eligibility →
Active, not recruitingPhase 1, Phase 2
Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
Updated 2026-05-15 · NCT06827002See eligibility →
Related treatments
How current is this page?
The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.
Does appearing here mean I qualify?
No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.